The evidence of low expression of SST3 in normal tissues, together with its relatively high internalization efficiency among the other SST subtypes71 and high expression level of this receptor subtype in tumors, strongly supports its potential as therapeutic target in cancer. This evidence concerns the gene SST and cancer.